Stereotactic Radiation Therapy for Pediatric Sarcomas



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:4 - 40
Updated:11/9/2018
Start Date:November 2013
End Date:November 2021
Contact:Stephanie Terezakis, M.D.
Email:sterezak@jhmi.edu
Phone:443-287-7889

Use our guide to learn which trials are right for you!

A Phase II Study of Hyperfractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

The SBRT (stereotactic body radiation therapy) literature focuses on clinical outcomes in the
adult population. However, SBRT (stereotactic body radiation therapy) has a particularly
strong rationale for application in pediatrics given that high biologically effective doses
have been shown to increase control in histologies, such as sarcoma, which are common in the
pediatrics population (11,25). With stereotactic radiation therapy techniques, a reduction in
normal tissue dose surrounding the target lesion of interest may also be accomplished
resulting in lower toxicity. Given that pediatric patients with sarcomas, presenting with
limited metastases in lung and bone, are still considered to be a curable population with
aggressive local therapy, SBRT could have a significant impact on outcomes in oligometastatic
patients who may be otherwise unresectable (25-28).

Pediatric patients with sarcoma who have limited metastases are still potentially curable
with aggressive local therapy. However, conventional moderate dose radiation is unlikely to
provide durable local control. Given the recent technologic advances in radiation delivery,
it is now possible to deliver tumoricidal doses, using stereotactic radiation over a short
time course with highly focal techniques. Stereotactic radiation has proven efficacious in
the intracranial setting and in multiple extracranial sites in adults. It has not yet been
well studied in the pediatrics population where there is a particularly strong rationale due
to the ablative doses that can be delivered to tumor while simultaneously reducing high dose
to normal tissues. The proposed trial is a single arm phase II study to determine the
efficacy of SBRT in pediatric sarcomas with surgically unresectable metastatic disease.
Oligometastatic sites eligible for treatment in this study include bony sites of disease.
SBRT will be delivered to each eligible site to a total dose of 4000 delivered in 5 fractions
of 800 per fractions each day. Following completion of SBRT, patients will undergo treatment
response assessment with the use of diagnostic imaging, clinical examination, and completion
of the Brief Pain Inventory to assess quality of life. The primary objective of this study is
to determine the efficacy of SBRT delivered to a dose of 4000 in 5 fractions of 800 each for
patients greater than 3 years of age and < 40 years of age with metastatic disease of bone
secondary to pediatric sarcoma. The secondary objectives of this study include describing the
toxicity of SBRT with this regimen; assessing clinical response rate of each target lesion;
assessing long-term clinical outcomes; and assessing quality of life following completion of
treatment. For patients with potentially curable oligometastatic disease, surgical resection
in conjunction with systemic therapy remains the standard of care. Patients on this study
will continue to receive chemotherapy outside of the 2 week window for SBRT. Issues that may
limit participation include our inability to assess late effects that may not develop till at
least 10 years after therapy. For this reason, we will limit the population in this study to
patients who are surgically unresectable and would be otherwise incurable with current
standard systemic therapies.

Inclusion Criteria:

- confirmed sarcoma of the soft tissue or bone

- must have measurable disease via CT scan

- tumor malignancies must meet certain criteria to be eligible

- greater than 3 years of age

- less than or equal to 40 years of age

- life expectancy of at least 9 months

- adequate performance status

- ability to understand and willingness to sign informed consent document

Exclusion Criteria:

- patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering
the study

- patients who have had any prior radiotherapy to the treatment site(s)

- patients may not participate on any other treatment protocol while they are receiving
treatment on this protocol and for up to 3 months after these protocol treatments have
ended

- pregnant women

- refusal of women of child bearing potential to take a pregnancy test prior to
treatment
We found this trial at
5
sites
Rochester, Minnesota 55905
Principal Investigator: Nadia Laack, MD
Phone: 507-284-4561
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Baltimore, Maryland 21231
410-955-6190
Phone: 443-287-7889
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Matthew Krasin, MD
Phone: 901-595-3565
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Stanford, California 94305
Principal Investigator: Iris Gibbs, MD
Phone: 650-736-1480
?
mi
from
Stanford, CA
Click here to add this to my saved trials
5255 Loughboro Rd NW
Washington, District of Columbia 20016
(202) 537-4000
Sibley Memorial Hospital Sibley Memorial Hospital, in Northwest Washington, D.C., has a distinguished history of...
?
mi
from
Washington,
Click here to add this to my saved trials